Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas
Last updated on July 2021Recruitment
- Recruitment Status
- Withdrawn
- Estimated Enrollment
- 10
Summary
- Conditions
- Malignant Melanoma
- Type
- Interventional
- Phase
- Early Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 99 years
- Gender
- Both males and females
Description
This is an open-label, single arm, study assessing the activity of fluvastatin in shifting the transcriptome in melanoma. Subjects with melanoma will be asked to participate and all subjects will receive the study drug, fluvastatin, for 2 weeks. The primary objective of this study to determine wheth...
This is an open-label, single arm, study assessing the activity of fluvastatin in shifting the transcriptome in melanoma. Subjects with melanoma will be asked to participate and all subjects will receive the study drug, fluvastatin, for 2 weeks. The primary objective of this study to determine whether administration of fluvastatin changes the melanoma transcriptome The secondary objective of this study is to determine whether administration of fluvastatin changes the gene expression profile of Class 2 melanoma to Class 1 melanoma.
Tracking Information
- NCT #
- NCT04285749
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Wesley Yu, MD University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Get Well Soon